Sonata Therapeutics
Nathan Edwards is an experienced finance professional with a career spanning over 17 years in the biotechnology and consulting sectors. Currently, Nathan serves as the Head of Finance at Sonata Therapeutics since June 2022. Prior to this, Nathan held various leadership roles at Flagship Pioneering, including Senior Director and Director, from October 2020 to June 2022. Nathan's extensive experience also includes a tenure at Biogen, where roles ranged from Associate Director to Senior Analyst from September 2012 to October 2020. Nathan began the professional journey at Ernst & Young as a Supervisory Senior from September 2006 to September 2012. Nathan holds a Bachelor's degree in Accounting from Fairfield University, earned between 2002 and 2006.
This person is not in the org chart
This person is not in any teams
Sonata Therapeutics
Sonata Therapeutics is a new, Boston-based Flagship Pioneering company revolutionizing the world’s understanding of the cellular microenvironment and its importance to human biology and disease. Our product-platform creates drugs based on a systematic, comprehensive characterization of the microenvironment in diseases with high unmet medical need. Through our pioneering science, we identify new targets for therapeutics that induce the release of a programmed diversity of signals with the potential for significant patient impact. Our employees are exceptionally passionate, accountable, collaborative, and innovative. Sonata Therapeutics was founded by Flagship Pioneering, an organization dedicated to the origination and development of first-in-category life sciences companies. Since 2000, Flagship has originated and fostered the development of nearly 100 scientific ventures resulting in $20+ billion in aggregate value, 500+ issued patents, and more than 50 clinical trials for novel therapeutic agents.